This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Implied Volatility Surging for Cigna Group (CI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Cigna Group (CI) stock based on the movements in the options market lately.
Here's Why Investors Should Retain Cigna (CI) Stock Now
by Zacks Equity Research
Cigna (CI) remains well-poised for growth on the back of continually growing premiums within its Cigna Healthcare unit. Solid cash-generating abilities also enable it to deploy capital.
Here is What to Know Beyond Why Cigna Group (CI) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching Cigna (CI) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Cigna (CI) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Cigna (CI) closed the most recent trading day at $261.78, moving +0.6% from the previous trading session.
Cigna (CI) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Cigna (CI) closed at $272.90 in the latest trading session, marking a +1.28% move from the prior day.
Zacks Industry Outlook Highlights UnitedHealth, The Cigna, Humana, Centene and Molina Healthcare
by Zacks Equity Research
UnitedHealth, The Cigna, Humana, Centene and Molina Healthcare are part of the Zacks Industry Outlook article.
5 HMO Stocks to Watch Despite Elevated Tech Costs, Nursing Shortage
by Debasmita Chatterjee
Improved premiums cropping from a solid customer base might aid the Medical-HMO industry. However, an escalating expense level and an acute shortage of nurses are roadblocks. Stocks like UNH, CI, HUM, CNC and MOH are likely to navigate the industry storms.
Is Trending Stock Cigna Group (CI) a Buy Now?
by Zacks Equity Research
Cigna (CI) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Cigna (CI) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Cigna (CI) closed at $273.05, marking a -0.94% move from the previous day.
Should IQ Chaikin U.S. Large Cap ETF (CLRG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for CLRG
Is IQ Chaikin U.S. Large Cap ETF (CLRG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for CLRG
Teladoc's (TDOC) BetterHelp Faces FTC Hurdle, to Pay $7.8M
by Zacks Equity Research
Teladoc's (TDOC) BetterHelp business is expected to continue implementing more comprehensive privacy standards.
Cigna Group (CI) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Cigna (CI) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Cigna Corporation (CI) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Cigna (CI) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Molina Healthcare (MOH) Q4 Earnings Beat on Solid Medicaid Unit
by Zacks Equity Research
Molina Healthcare's (MOH) fourth-quarter results benefit from its strong Medicaid and Medicare businesses. Management expects 2023 adjusted EPS at a minimum of $19.75.
Radian Group (RDN) Q4 Earnings Top Estimates, Decrease Y/Y
by Zacks Equity Research
Radian Group's (RDN) Q4 results reflect higher monthly premium policy insurance in force, decline in single premium policy insurance in force, offset by higher expenses.
Prudential Financial (PRU) Q4 Earnings Miss, Decrease Y/Y
by Zacks Equity Research
Prudential Financial's (PRU) fourth-quarter results reflect a poor performance across most of the segments, lower premiums and net investment income, offset by lower expenses.
Assurant (AIZ) Q4 Earnings & Revenues Beat, Premiums Rise Y/Y
by Zacks Equity Research
Assurant's (AIZ) Q4 results reflect higher average insured values, premium rates and lender-placed policies in force and growth in Connected Living, partly offset by higher expenses.
Ensign Group (ENSG) Shares Down 2% Since Q4 Earnings Release
by Zacks Equity Research
Ensign Group's (ENSG) fourth-quarter results indicate higher skilled services revenue and improved occupancies, partly offset by the increased cost of services.
Cigna (CI) Q4 Earnings Top on U.S. Commercial Unit, Dividend Up
by Zacks Equity Research
Cigna's (CI) fourth-quarter results reflect the strong contribution from the Evernorth segment. Management sanctions a 10% increase in the quarterly dividend.
Cigna (CI) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Cigna (CI) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Cigna (CI) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Cigna (CI) delivered earnings and revenue surprises of 2.48% and 0.37%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights Stride, Herc Holdings, ONEOK and Cigna
by Zacks Equity Research
Stride, Herc Holdings, ONEOK and Cigna have been highlighted in this Screen of The Week article.
Add These 4 Stocks With Amazing Interest Coverage Ratio
by Sumit Singh
A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Stride (LRN), Herc Holdings (HRI), ONEOK (OKE) and Cigna (CI) are strong enough to meet financial obligations.
Time to Buy Cigna or Regeneron Stock Before Earnings?
by Shaun Pruitt
Among the Finance and Medical sector, Cigna (CI) and Regeneron Pharmaceuticals (REGN) are both leaders in their respective industries and have had strong performances over the last year as the broader market and economy declined.